01Veradermics reported Q2 2026 earnings per share of -$0.58, beating the consensus estimate of -$0.63 by $0.05 per share on August 11, 2026.
02The company's stock currently trades at $110.10 following the earnings release.
03Q1 2026 results showed a significant miss with EPS of -$1.32 versus the -$0.79 estimate, representing a -67.1% surprise, indicating recent improvement in performance.
04Revenue figures for Q2 were not disclosed in the article, limiting assessment of overall business performance beyond earnings per share metrics.
Earnings Results
Veradermics (NYSE:MANE) reported quarterly earnings results on August 11, 2026 that exceeded analyst expectations.
The company reported earnings per share of $-0.58, beating the consensus estimate of $-0.63 by $0.05 per share. Revenue came in at , meeting the estimate of .
Company Overview
Veradermics's stock moved following the earnings release. The stock currently trades at $110.10.
Veradermics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Veradermics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.